The Genomics Issue

Arndt, Kenneth A.

doi:10.1001/archderm.137.11.1409

Arch Dermatol

2001

DOI: 10.1001/archderm.137.11.1409

|View full text |Cite

The Genomics Issue

Kenneth A. Arndt¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2001

2008

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 13 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…

In 2001, JAMA and its related journals published a special genomics issue at a time when the sequencing of the human genome was finishing. 1 This issue of the Archives on clinically relevant genetics and genomics comes a mere 7 years later and heralds the rapid progress in deciphering the human genome and the genetic basis of disease. This issue showcases a few of the latest advances in clinical genetics of the skin.

…”

mentioning

confidence: 99%

Dermatology in the Postgenomic Era

Oro¹

2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…

…”

mentioning

confidence: 99%

Dermatology in the Postgenomic Era

Oro¹

2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

Cytogenetic alterations in nonmelanoma skin cancer: A review

Ashton

Carless

Griffiths

2005

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Since the advent of cytogenetic analysis, knowledge about fundamental aspects of cancer biology has increased, allowing the processes of cancer development and progression to be more fully understood and appreciated. Classical cytogenetic analysis of solid tumors had been considered difficult, but new advances in culturing techniques and the addition of new cytogenetic technologies have enabled a more comprehensive analysis of chromosomal aberrations associated with solid tumors. Our purpose in this review is to discuss the cytogenetic findings on a number of nonmelanoma skin cancers, including squamous- and basal cell carcinomas, keratoacanthoma, squamous cell carcinoma in situ (Bowen's disease), and solar keratosis. Through classical cytogenetic techniques, as well as fluorescence-based techniques such as fluorescence in situ hybridization and comparative genomic hybridization, numerous chromosomal alterations have been identified. These aberrations may aid in further defining the stages and classifications of nonmelanoma skin cancer and also may implicate chromosomal regions involved in progression and metastatic potential. This information, along with the development of newer technologies (including laser capture microdissection and comparative genomic hybridization arrays) that allow for more refined analysis, will continue to increase our knowledge about the role of chromosomal events at all stages of cancer development and progression and, more specifically, about how they are associated with nonmelanoma skin cancer.

show abstract

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high‐risk cutaneous melanoma

Mocellin

Fiore

Guarnieri

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Detection of circulating tumor cells (CTCs) might improve current staging procedures by identifying a subgroup of patients with minimal residual disease and thus a higher risk of disease recurrence. Forty patients with >2-mm-thick cutaneous melanoma with or without lymph node metastasis were enrolled. After standard radical surgery and adjuvant therapy in case of lymph node metastasis, patients were followed up with routine physical and radiologic assessments as well as serial PCR-based analysis of CTCs using 2 melanoma markers (tyrosinase and Melan-A/Mart-1). After a median follow-up of 30 months, 18 patients had disease recurrence and 28 were PCR-positive before the disease became clinically evident. The sensitivity of the molecular test was 83%. Median time to PCR positivity and median PCR-torelapse time were 12 and 8 months, respectively. At multivariate analysis, PCR positivity was an independent predictor of disease recurrence (hazard ratio ‫؍‬ 2.06, 95% CI 1.07-3.35; p ‫؍‬ 0.03). Among high-risk melanoma patients, serial PCRbased analysis of CTCs can identify a subgroup at higher risk of disease recurrence, with clinically significant advance. Therefore, CTC detection might be employed for the selection of patients for adjuvant treatment and during follow-up for early indication of therapeutic failure.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Genomics Issue

Cited by 13 publications

References 0 publications

Dermatology in the Postgenomic Era

Dermatology in the Postgenomic Era

Cytogenetic alterations in nonmelanoma skin cancer: A review

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high‐risk cutaneous melanoma

Contact Info

Product

Resources

About